Celgene's CEO Wants to Make the Biotech's Best-Selling Drug Obsolete — Here's Why That's Great for Investors

Revlimid is Celgene’s biggest moneymaker by far. But here’s how and why CEO Mark Alles wants to make it disappear. …read more

Source:: Yahoo Finance

      

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.